Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Navarro, J. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Navarro, J. F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2003) 18: 2222-2226
© 2003 European Renal Association-European Dialysis and Transplant Association

Editorial Comment

In the erythropoietin era, can we forget alternative or adjunctive therapies for renal anaemia management? The androgen example

Juan F. Navarro

Nephrology Service and Research Unit, Universitary Hospital Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Tenerife, Spain

Correspondence and offprint requests to: Juan F. Navarro, MD, Nephrology Service, Hospital Nuestra Señora de Candelaria, 38010 Santa Cruz de Tenerife, Tenerife, Spain. Email: jnavgon@gobiernodecanarias.org

Keywords: anaemia; androgens; nandrolone; nutrition; recombinant human erythropoietin

The first 150 words of the full text of this article appear below.

Introduction

Anaemia is an almost-universal complication of renal insufficiency with significant consequences such as fatigue, reduced stamina, decreased cognition, sexual dysfunction, impaired immunity and diminished quality of life. It also plays a critical role in the development of the structural and functional alterations of the cardiovascular system that are associated with uraemia, and contributes to accelerated atherosclerosis [1–4]. Nowadays, it is widely recognized that anaemia bears a great responsibility for the increased morbidity and mortality of patients with end-stage renal disease (ESRD).

Recombinant human erythropoietin: a triumph of modern medicine

The advent of recombinant human erythropoietin (rHuEPO) represented a revolution in the field of nephrology, allowing: avoidance of blood transfusions, reduction in the risk of sensitization, prevention of iron overload and improved exercise tolerance, cognitive capacity, sexual function and quality of life. The treatment of anaemia was deeply transformed. Still, several questions and problems remain concerning the use of rHuEPO. For instance, switching from the . . . [Full Text of this Article]

Androgens: a matter of persistence

Conclusions


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
D. Silverberg, D. Wexler, M. Blum, D. Schwartz, and A. Iaina
The use of androgens in anaemia resistant to erythropoietin and i.v. iron in patients with heart and renal failure
Nephrol. Dial. Transplant., April 1, 2004; 19(4): 1021 - 1021.
[Full Text] [PDF]